Navigating the evolving therapeutic landscape in advanced prostate cancer
Navigating the evolving therapeutic landscape in advanced prostate cancer
复制标题
DOI：
10.1016/j.urolonc.2017.01.020
复制
发表时间：
2017-05-01
影响因子：
2.7
通讯作者：
Sartor, Oliver
中科院分区：
文献类型：
--
作者：
Crawford, E. David;Petrylak, Daniel;Sartor, Oliver
前列腺癌是男性最常见的癌症原因，每年每10万男性中有137.9例新发病例。前列腺癌的5年生存率非常高。在接受前列腺癌最先进治疗的男性中，高达20%的人将在5年内发展为去势抵抗性前列腺癌（CRPC），最近的研究中，转移性CRPC患者的中位生存期约为15至36个月。随着过去5年来治疗CRPC的几种新药的出现，临床医生面临的挑战是如何最好地排序或联合收割机治疗或两者兼而有之以优化结果。更好地了解疾病过程和雄激素受体作为治疗和耐药性靶点的作用，导致考虑将生物标志物作为一种方法，以帮助为给定患者选择合适的药物，因为患者对不同药物的反应或耐受性不同。目前正在进行研究，以确定与结局指标相关的新的预后生物标志物，以及预测治疗反应或耐药的预测性生物标志物。讨论了晚期前列腺癌的治疗和与生物标志物相关的研究。(C)2017爱思唯尔公司All rights reserved.
Prostate cancer is the most common cause of cancer in men, with 137.9 new cases per 100,000 men per year. The overall 5-year survival rate for prostate cancer is very high. Up to 20% of men who undergo state-of-the art treatment for prostate cancer will develop castration-resistant prostate cancer (CRPC) within 5 years, with median survival for those with metastatic CRPC ranging from approximately 15 to 36 months in recent studies. With the advent of several new drugs in the past 5 years to treat CRPC, the challenge facing clinicians is how to best sequence or combine therapies or both to optimize outcomes. A better understanding of the disease process and the role of the androgen receptor as a target for both therapy and resistance have led to the consideration of biomarkers as an approach to aid in selecting the appropriate agent for a given patient as patients respond to or tolerate different drugs differently. Research to identify new prognostic biomarkers, which are associated with outcome measures, as well as predictive biomarkers, which predict response or resistance to therapy is ongoing. The treatment of advanced prostate cancer and the research related to biomarkers are discussed. (C) 2017 Elsevier Inc. All rights reserved.